STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELVN
  4. [Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Enliven Therapeutics (ELVN) CSO-linked trust sells 132,500 shares in January

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. insider activity shows that a trust associated with Chief Scientific Officer Joseph P. Lyssikatos sold a total of 132,500 shares of common stock in early January 2026. The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee, reported sales of 7,500 shares at a weighted average price of $20.1282 on 01/08/2026, followed by 33,802 shares at $24.9238 on the same date. On 01/09/2026, the trust sold 41,198 shares at a weighted average price of $24.9008 and 50,000 shares at $29.1343. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024, and after the final sale, the trust beneficially owned 765,188 shares.

Positive

  • None.

Negative

  • None.
Insider Lyssikatos Joseph P
Role CHIEF SCIENTIFIC OFFICER
Sold 132,500 shs ($3.48M)
Type Security Shares Price Value
Sale Common Stock 41,198 $24.9008 $1.03M
Sale Common Stock 50,000 $29.1343 $1.46M
Sale Common Stock 7,500 $20.1282 $151K
Sale Common Stock 33,802 $24.9238 $842K
Holdings After Transaction: Common Stock — 815,188 shares (Indirect, See footnote)
Footnotes (1)
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lyssikatos Joseph P
(Last) (First) (Middle)
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
(Street)
BOULDER CO 80301
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF SCIENTIFIC OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/08/2026 S(1) 7,500 D $20.1282(2) 890,188 I See footnote(3)
Common Stock 01/08/2026 S(1) 33,802 D $24.9238(4) 856,386 I See footnote(3)
Common Stock 01/09/2026 S(1) 41,198 D $24.9008(5) 815,188 I See footnote(3)
Common Stock 01/09/2026 S(1) 50,000 D $29.1343(6) 765,188 I See footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
2. This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
4. This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Ben Hohl, by power of attorney 01/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider involved in this ELVN Form 4 filing?

The filing relates to Joseph P. Lyssikatos, who serves as the Chief Scientific Officer of Enliven Therapeutics, Inc. The reported shares are held by The Lyssikatos Revocable Trust 12/15/2011, for which he acts as trustee.

How many Enliven Therapeutics (ELVN) shares were sold in this Form 4?

The transactions report aggregate sales of 132,500 shares of common stock, consisting of 7,500 shares, 33,802 shares, 41,198 shares, and 50,000 shares sold over two days.

On what dates did the ELVN insider share sales occur?

The reported sales of Enliven Therapeutics common stock took place on 01/08/2026 and 01/09/2026, as disclosed in Table I of the filing.

What prices were the ELVN shares sold for in this insider transaction?

The weighted average sale prices were $20.1282, $24.9238, $24.9008, and $29.1343 per share, with each transaction executed in multiple trades within the stated price ranges.

How many Enliven Therapeutics shares did the trust hold after these sales?

Following the last reported transaction on 01/09/2026, The Lyssikatos Revocable Trust 12/15/2011 beneficially owned 765,188 shares of Enliven Therapeutics common stock.

Were the ELVN insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

Who actually holds the ELVN shares reported in this Form 4?

The filing explains that the shares are held by The Lyssikatos Revocable Trust 12/15/2011, for which the reporting person serves as trustee, and the ownership is reported as indirect.